NEW YORK (360Dx) – Qiagen said this week that it has joined Cancer-ID, a public-private consortium that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

With 36 partners from 13 countries, the Cancer-ID consortium is a project of the Innovative Medicines Initiative, a European public-private program that aims to speed up the development of better and safer medicines for patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.